Explore the Agenda

8:00 am Morning Coffee and Check-in

8:55 am Chair’s Opening Remarks

Co-Founder & Vice President, Biologics & Scientific, Mythic Therapeutics

Exploring Bispecific Cell Engagers & How Refining Antibody Affinity Can Help Predict Therapeutic Outcomes & Improve Specificity

9:00 am Creating Conditionally Acting, Multifunctional Cell Engagers with Enhanced Target Selectivity & Reduced Toxicity Potential

Chief Executive Officer, Orionis Biosciences
  • Tuning antibody arms: optimizing for affinity and epitope recognition to instill cooperative, selective target binding
  • Integrating tuned effector modules to deliver target-selective, conditional cytokine receptor signalling
  • Combining and tuning antibody arms and effector payloads in the design and engineering of novel T cell engagers

9:30 am Session Reserved for Invenra

10:00 am Morning Break & Speed Networking

The perfect opportunity to kickstart new connections in this speed networking session designed to help you meet a high volume of fellow bispecific experts, exchange insights, and set the stage for deeper conversations throughout the summit.

Exploring the Next Generation of Bispecific Antibodies to Enhance Efficacy & Safety for Autoimmune Indications

11:00 am Exploring a Novel Mechanism of Action With the Development of TCR-PD1 Agonist Bispecifics For The Treatment of Autoimmune Diseases

Chief Technology Officer, Immunocore
  • Aiming to deliver tissue-specific TCR-based therapeutics
  • Adapting the ImmTAC platform with a novel effector function to address autoimmune diseases
  • Exploring the Development of a beta-cell targeted Immune Suppressive PD-1 Agonist Bispecific to treat type I diabetes

11:30 am Session Reserved for Alloy Therapeutics

12:00 pm Lunch

1:00 pm ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways

Director, Immunology, Zymeworks
  • Exploring how ZW1528 binds to both IL-4Ra and IL-33, and mediates potent blockade of IL-4, IL-13 and IL-33 enabling a broad and simultaneous inhibition of key inflammatory pathways
  • Demonstrating translational relevance as ZW1528 inhibits Type 2 and non-Type 2 responses in vitro in primary immune cells of COPD patients, effectively modulating diverse immune pathways across patient subtypes
  • Investigating how ZW1528 demonstrates IgG-like PK and biomarkers of target blockade in the NHP, supporting clinical viability through favourable pharmacokinetics and validated target engagement

1:30 pm Conditionally active 41BB Costimulatory CD19 x CD20 T Cell engager designed for deeper and durable responses and minimal cytokine release for Autoimmune Diseases

Chief Executive Officer, Synaptimmune Therapeutics
  • Costimulation built in CD19 x CD20 T Cell Engager (TCE) to achieve CAR-T like potency, immune reset, and efficacy for Autoimmune diseases
  • Conditional Activation of TCE only in the presence of antigen engagement overcomes cytokine release syndrome associated with conventional TCEs
  • Shows increased potency and efficacy in the humanized SLE mouse model compared to benchmark TCE BlinatumomabTM and other CD19 and CD20 TCE’s in development for Autoimmune Diseases

2:15 pm Afternoon Break & Poster Session

This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of bispecific experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work. Additionally, you will have the chance to review others’ posters displaying cutting-edge work from drug discovery right through to exciting clinical trial updates.

2:45 pm Session Reserved for Alloy Therapeutics

Strategic Target Selection for Optimizing Bispecific Design & Function

3:15 pm Panel Discussion: Strategic Target Selection for Optimizing Bispecific Design & Function

Associate Director & Group Leader, Novartis AG
Senior Medical Director, Drug Safety Liason, SOTIO
Co-Founder & Vice President, Biologics & Scientific, Mythic Therapeutics
Fellow Scientist, Regeneron
Founder and Chief Executive Officer, Lyvgen Biopharma

This panel will examine how aligning target biology, mechanism of action, and bispecific format is critical to therapeutic success. Experts will explore strategies for selecting and validating novel targets, addressing tumor heterogeneity, and optimizing design parameters to enhance efficacy while managing safety.

  • How do you determine whether a target’s biology aligns with the intended mechanism of action of your bispecific construct?
  • What are the key molecular design considerations? Looking at considerations, such as affinity, format, and valency for a selected target
  • How can we better predict and manage unexpected biology that arises from targeting a molecule in a specific disease context?
  • What approaches are most effective for validating novel targets, particularly in solid tumors with heterogeneous expression?
  • How do different bispecific modalities (e.g., T-cell engagers, costimulatory bispecifics, ADCs) influence target selection strategy?
  • How do you balance the therapeutic window by assessing target expression across tumor versus normal tissue to mitigate toxicity?

4:15 pm Session Reserved for BSP Pharmaceuticals

4:30 pm Chair’s Closing Remarks

Co-Founder & Vice President, Biologics & Scientific, Mythic Therapeutics

4:45 pm End of Conference Day One